VHCP Management
Latest statistics and disclosures from VHCP Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Dbv Technologies, HRTX, CHRS, BCRX, Flamel Technologies, and represent 71.60% of VHCP Management's stock portfolio.
- Added to shares of these 3 stocks: Ra Pharmaceuticals, BCRX, Ocera Therapeutics.
- Started 1 new stock position in Ra Pharmaceuticals.
- Reduced shares in these 4 stocks: Zafgen, BGNE, , RGNX.
- Sold out of its positions in Achillion Pharmaceuticals, BGNE, RGNX, Zafgen.
- VHCP Management was a net seller of stock by $-761k.
- VHCP Management has $93M in assets under management (AUM), dropping by -8.55%.
- Central Index Key (CIK): 0001479355
Portfolio Holdings for VHCP Management
VHCP Management holds 21 positions in its portfolio as reported in the December 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dbv Technologies | 33.5 | $31M | 457k | 68.13 |
|
|
| Heron Therapeutics (HRTX) | 15.4 | $14M | 1.1M | 13.10 |
|
|
| Coherus Biosciences (CHRS) | 9.2 | $8.6M | 306k | 28.15 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 7.9 | $7.3M | +14% | 1.2M | 6.33 |
|
| Flamel Technologies | 5.6 | $5.2M | 500k | 10.39 |
|
|
| Ra Pharmaceuticals | 3.8 | $3.5M | NEW | 233k | 15.19 |
|
| Adverum Biotechnologies | 3.4 | $3.2M | 1.1M | 2.90 |
|
|
| Lipocine | 3.4 | $3.1M | 850k | 3.68 |
|
|
| Colucid Pharmaceuticals | 2.7 | $2.5M | 68k | 36.40 |
|
|
| Axovant Sciences | 2.5 | $2.3M | 184k | 12.42 |
|
|
| Ocera Therapeutics | 2.1 | $1.9M | +6% | 912k | 2.10 |
|
| Ascendis Pharma A S (ASND) | 2.0 | $1.8M | 90k | 20.24 |
|
|
| Edge Therapeutics | 1.8 | $1.7M | 135k | 12.50 |
|
|
| D Stemline Therapeutics | 1.6 | $1.4M | 135k | 10.70 |
|
|
| Alcobra | 1.5 | $1.4M | 659k | 2.10 |
|
|
| ARCA biopharma | 1.4 | $1.3M | 462k | 2.85 |
|
|
| Akari Therapeutics | 1.2 | $1.1M | 158k | 7.04 |
|
|
| Cytomx Therapeutics (CTMX) | 0.8 | $706k | 64k | 11.00 |
|
|
| Audentes Therapeutics | 0.3 | $274k | 15k | 18.27 |
|
|
| Pronai Therapeutics | 0.1 | $84k | 56k | 1.50 |
|
|
| Aeglea Biotherapeutics | 0.0 | $26k | 6.0k | 4.33 |
|
Past Filings by VHCP Management
SEC 13F filings are viewable for VHCP Management going back to 2010
- VHCP Management 2016 Q4 filed Feb. 13, 2017
- VHCP Management 2016 Q3 filed Nov. 14, 2016
- VHCP Management 2016 Q2 filed Aug. 12, 2016
- VHCP Management 2016 Q1 filed May 13, 2016
- VHCP Management 2015 Q4 filed Feb. 12, 2016
- VHCP Management 2015 Q3 filed Nov. 13, 2015
- VHCP Management 2015 Q2 filed Aug. 13, 2015
- VHCP Management 2015 Q1 filed May 14, 2015
- VHCP Management 2014 Q4 filed Feb. 13, 2015
- VHCP Management 2014 Q3 filed Nov. 13, 2014
- VHCP Management 2014 Q2 filed Aug. 13, 2014
- VHCP Management 2014 Q1 filed May 14, 2014
- VHCP Management 2013 Q4 filed Feb. 13, 2014
- VHCP Management 2013 Q3 filed Nov. 15, 2013
- VHCP Management 2013 Q2 filed Aug. 14, 2013
- VHCP Management 2013 Q1 filed May 14, 2013